Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
A minimalist illustration of a pill and molecular structure representing AI drug discovery.

Jul 20, 2026

AI Drug Discovery

Insilico Medicine has made significant strides in AI drug discovery, as evidenced by its latest advancement into Phase III trials for Rentosertib, a treatment for idiopathic pulmonary fibrosis (IPF).This development showcases the capabilities of Insilico's Pharma.AI platform, which effectively identifies disease targets and designs new drug candidates. The AI-driven approach not only streamlines the drug development process—from target identification to clinical trial optimization—but also highl
A glass vial and research notebook in a dimly lit lab

Jul 20, 2026

Bristol Myers Squibb Expands Partnership with Nvidia | PharmExec

Bristol Myers Squibb is significantly enhancing its AI capabilities through a partnership with Nvidia, aiming to establish a highly advanced AI infrastructure in the life sciences sector.In a strategic move, Bristol Myers Squibb (BMS) is expanding its AI computing framework by integrating Nvidia's DGX SuperPOD, which features the Vera Rubin NVL72 systems. This new infrastructure is touted to deliver up to ten times the performance efficiency per megawatt compared to previous systems, thereby enh
DGX SuperPOD in a laboratory

Jul 20, 2026

Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory

Bristol Myers Squibb (BMS) is enhancing its computational capabilities by expanding its collaboration with Nvidia through the deployment of a DGX SuperPOD featuring DGX Vera Rubin NVL72 systems. This upgrade positions BMS to possess the most advanced Nvidia infrastructure dedicated to life sciences, building on nearly three years of partnership with Nvidia.The new Vera Rubin architecture significantly boosts performance, delivering up to ten times greater efficiency per megawatt compared to prev
A minimalist illustration of a molecule and DNA strand for drug discovery.

Jul 20, 2026

BMS Deploys NVIDIA AI Infrastructure for Drug Discovery

Bristol Myers Squibb (BMS) is significantly enhancing its AI capabilities through a collaboration with NVIDIA, focusing on the deployment of advanced DGX SuperPOD systems. This initiative aims to bolster AI-driven drug discovery efforts across BMS’s research portfolio, marking a milestone as it establishes one of the most powerful and energy-efficient AI infrastructures within the life sciences sector.The integration of NVIDIA’s BioNeMo platform will allow BMS to leverage AI models for molecular
A minimalist illustration of a computer chip with energy waves, symbolizing advanced AI infrastructure.

Jul 20, 2026

Bristol Myers Squibb to build the most powerful AI factory in life sciences with NVIDIA

Bristol Myers Squibb (BMS) is set to enhance its computational capabilities by deploying an NVIDIA DGX SuperPOD, establishing one of the most advanced AI infrastructures in the life sciences sector.This new infrastructure will significantly boost BMS's computational power and efficiency, allowing for up to ten times better performance per megawatt compared to previous systems. This advancement enables the company to tackle more complex AI tasks without a proportional increase in energy use, alig
A vial of liquid medication on a laboratory countertop in a dimly lit setting.

Jul 20, 2026

Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer

Bristol Myers Squibb (BMS) has joined the trend of pharmaceutical companies announcing the construction of large AI supercomputers, marking a significant step in leveraging advanced computational power for drug development.In a recent announcement, BMS revealed its plans to build what it claims will be the largest AI supercomputer in the life sciences sector. This follows similar declarations from other pharma companies within the past nine months. Initially, BMS partnered with NVIDIA three year
A flat design of a drug molecule silhouette

Jul 19, 2026

AI-Driven Discovery Platforms

Takeda has entered a strategic partnership with Insilico Medicine to leverage the Pharma AI suite for early-stage drug discovery across various therapeutic areas.This collaboration grants Takeda exclusive global rights to develop, manufacture, and commercialize drug candidates identified through Insilico's AI-driven discovery process. Insilico will spearhead the discovery phase, while Takeda will take selected therapies into clinical development.The Pharma.AI suite encompasses tools such as Pand
A flat illustration of a molecule representing retrosynthesis in a minimalist style.

Jul 17, 2026

Retrosynthesis software bridges pharma agrochemicals and fragrance sectors with advanced route design

Recent advancements in retrosynthesis software are revolutionizing the way chemists across pharmaceuticals, agrochemicals, and fragrance industries approach synthetic route design. Platforms like SYNTHIA utilize expert-coded reaction rules along with extensive chemical libraries to facilitate the synthesis of complex molecules. This technology significantly enhances the efficiency of the design process, allowing for more innovative solutions in drug development, agricultural chemicals, and fragr
Flat design illustration of a drug compound and clinical trial symbol

Jul 17, 2026

How well are AI-discovered drugs faring in the clinic?

The integration of AI in drug discovery is still in its nascent stages, with mixed results in clinical trials. While AI has the potential to revolutionize the pharmaceutical landscape, the journey from AI-driven discovery to clinical success is fraught with challenges.AI has emerged as a promising tool for accelerating drug research and development, traditionally a lengthy and expensive process. Although some AI-discovered drugs have shown early promise in phase 1 trials, their performance in la
A minimalist representation of a biological sample in a dark color scheme.

Jul 17, 2026

Antwerp’s Sightera Biosciences raises €3 million to scale its patient-derived AI drug discovery platform

Sightera Biosciences, a startup based in Antwerp, has successfully secured €3 million in pre-Seed funding to enhance its AI-driven drug discovery platform, which focuses on patient-derived biological data. This financing round was led by Entourage, Anacura, and QBIC, and the company aims to expand its team and accelerate the development of its oncology and fibrosis programs.The innovative approach of Sightera lies in its unique training methodology for its AI models. Instead of relying on generi
A test tube with antibody solution on a lab table

Jul 17, 2026

Argenx Partners With Chai Discovery for AI Antibody...

Chai Discovery has partnered with argenx to leverage AI for antibody discovery, marking a significant advancement in the life sciences sector.Chai Discovery, based in San Francisco, has formed a collaboration with argenx, providing the immunology firm with early access to its generative AI platform aimed at de novo antibody discovery. This partnership is notable as it is the fourth disclosed collaboration for Chai within a span of seven months, following similar agreements with major pharmaceuti
A close-up of an organoid culture dish in a dimly lit lab, highlighting the intricate details of the tissue sample.

Jul 17, 2026

Reversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from 'extreme' patient biology first

Belgian biotech Sightera Biosciences has secured €3 million in pre-seed funding to advance its innovative AI drug discovery platform, which uniquely focuses on learning from treatment-resistant patients.Sightera's approach diverges from conventional AI drug discovery methods by starting with data from patients who do not respond to standard treatments. This "extreme biology" strategy involves creating organoids from these patients' tissues and conducting high-throughput drug screenings to gather